AcrAB-TolC directs efflux-mediated multidrug resistance in Salmonella enterica serovar typhimurium DT104

Antimicrobial Agents and Chemotherapy
Sylvie BaucheronA Cloeckaert

Abstract

Multidrug-resistant Salmonella enterica serovar Typhimurium definitive phage type 104 (DT104) strains harbor a genomic island, called Salmonella genomic island 1 (SGI1), which contains an antibiotic resistance gene cluster conferring resistance to ampicillin, chloramphenicol, florfenicol, streptomycin, sulfonamides, and tetracyclines. They may be additionally resistant to quinolones. Among the antibiotic resistance genes there are two, i.e., floR and tet(G), which code for efflux pumps of the major facilitator superfamily with 12 transmembrane segments that confer resistance to chloramphenicol-florfenicol and the tetracyclines, respectively. In the present study we determined, by constructing acrB and tolC mutants, the role of the AcrAB-TolC multidrug efflux system in the multidrug resistance of several DT104 strains displaying additional quinolone resistance or not displaying quinolone resistance. This study shows that the quinolone resistance and the decreased fluoroquinolone susceptibilities of the strains are highly dependent on the AcrAB-TolC efflux system and that single mutations in the quinolone resistance-determining region of gyrA are of little relevance in mediating this resistance. Overproduction of the AcrAB efflux...Continue Reading

References

Jan 1, 1972·Molecular & General Genetics : MGG·H Schmieger
Apr 2, 1999·Antimicrobial Agents and Chemotherapy·C E Briggs, P M Fratamico
Nov 5, 1999·The New England Journal of Medicine·K MølbakH C Wegener
Feb 23, 2000·BioTechniques·D Favre, J F Viret
Jun 1, 2000·Proceedings of the National Academy of Sciences of the United States of America·K A Datsenko, B L Wanner
Jul 7, 2000·The Journal of Antimicrobial Chemotherapy·E J Threlfall
Jul 29, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R CarnevaleF M Aarestrup
Jul 4, 2001·Veterinary Research·A Cloeckaert, E Chaslus-Dancla
Aug 10, 2001·Current Opinion in Structural Biology·V KoronakisC Hughes
Sep 20, 2001·Current Medicinal Chemistry·O Lomovskaya, W J Watkins
Jan 5, 2002·Journal of Biochemistry·Erika FujihiraAkihito Yamaguchi
Mar 14, 2002·The Journal of Membrane Biology·C AndersenV Koronakis
Aug 7, 2002·Proceedings of the National Academy of Sciences of the United States of America·Christian AndersenVassilis Koronakis
Oct 9, 2002·Current Protein & Peptide Science·H I Zgurskaya, H Nikaido
Oct 11, 2002·Nature·Satoshi MurakamiAkihito Yamaguchi
Nov 12, 2002·Journal of Bacteriology·Elena B TikhonovaHelen I Zgurskaya
Nov 28, 2002·Nature Biotechnology·Olga LomovskayaHiroshi Nikaido
Jan 14, 2003·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Sylvie BaucheronAxel Cloeckaert
Mar 12, 2003·Journal of Molecular Biology·Jeyanthy EswaranVassilis Koronakis
Mar 26, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Christopher A Elkins, Hiroshi Nikaido
Apr 4, 2003·International Journal of Antimicrobial Agents·UNKNOWN Members of the SFM Antibiogram Committee
Sep 2, 2003·Current Opinion in Structural Biology·Satoshi Murakami, Akihito Yamaguchi

❮ Previous
Next ❯

Citations

Jul 1, 2009·Epidemiology and Infection·A M SmithUNKNOWN Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA)
Mar 31, 2009·The Journal of Antibiotics·Kunihiko NishinoAkihito Yamaguchi
Jul 18, 2006·Nature Reviews. Microbiology·Laura J V Piddock
Nov 21, 2008·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Silke Feuerriegel, Peter Heisig
Apr 30, 2008·Antimicrobial Agents and Chemotherapy·Yousef M AbouzeedAxel Cloeckaert
Apr 15, 2006·Clinical Microbiology Reviews·Laura J V Piddock
Nov 8, 2006·Infection and Immunity·Diana M PosadasAngeles Zorreguieta
Jun 13, 2012·Microbiology and Molecular Biology Reviews : MMBR·Crystal L JonesDavid S Weiss
Nov 7, 2012·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Lucia Birosova, Maria Mikulasova
Aug 31, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Wei GuoHaoyan Wang
Apr 8, 2014·The Journal of Antimicrobial Chemotherapy·Anna FàbregaJordi Vila
Nov 19, 2014·Future Microbiology·Jessica M A BlairLaura J V Piddock
Jan 31, 2015·International Journal of Environmental Research and Public Health·Jody L AndersenManuel F Varela
Aug 12, 2009·Current Opinion in Microbiology·Jessica M A Blair, Laura J V Piddock
Nov 6, 2007·International Journal of Hygiene and Environmental Health·Brenda P MurphySéamus Fanning
Jul 17, 2007·International Journal of Antimicrobial Agents·Javier Sánchez-Céspedes, Jordi Vila
Jan 1, 2009·Microbial Biotechnology·Anna FàbregaJordi Vila
Jul 30, 2014·Annals of the New York Academy of Sciences·Aparna TatavarthyPhilip T Amuso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.